Literature DB >> 22514151

The interaction between BDNF and DRD2 in bipolar II disorder but not in bipolar I disorder.

Chih-Chun Huang1, Yun-Hsuan Chang, Sheng-Yu Lee, Shiou-Lan Chen, Shih-Heng Chen, Chun-Hsien Chu, San-Yuan Huang, Nian-Sheng Tzeng, I Hui Lee, Tzung Lieh Yeh, Yen Kuang Yang, Ru-Band Lu.   

Abstract

Bipolar I (BP-I) and bipolar II (BP-II) disorders are the two most common subtypes of bipolar disorder. However, most studies have not differentiated bipolar disorder into BP-I and BP-II groups, for which the underlying etiology differentiating these two subtypes remains unclear. The genetic association between both subtypes is essential for improving our understanding. The dopamine D2 receptor/ankyrin repeat and kinase domain containing 1 (DRD2/ANKK1), one of the dopaminergic pathways, as well as the brain-derived neurotrophic factor (BDNF) gene, were reported as candidate genes in the etiology of bipolar disorder. Therefore, we examined the contribution of the BDNF and DRD2/ANKK1 genes and their interaction to the differentiation of BP-I and BP-II. Seven hundred ninety-two participants were recruited: 208 with BP-I, 329 with BP-II, and 255 healthy controls. The genotypes of the BDNF and DRD2/ANKK1 Taq1A polymorphisms were determined using polymerase chain reactions plus restriction fragment length polymorphism analysis. A significant main effect for the Val/Val genotype of the BDNF Val66Met polymorphism predicted BP-II patients. The significant interaction effect for the Val/Val genotype of the BDNF Val66Met polymorphism and A1/A2 genotype of DRD2/ANKK1 Taq1A polymorphism was found only in BP-II patients. We provide initial evidence that the BDNF Val66Me and DRD2/ANKK1 Taq1A polymorphisms interact only in BP-II disorder and that BP-I and BP-II are genetically distinct.
Copyright © 2012 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22514151     DOI: 10.1002/ajmg.b.32055

Source DB:  PubMed          Journal:  Am J Med Genet B Neuropsychiatr Genet        ISSN: 1552-4841            Impact factor:   3.568


  7 in total

1.  Oxidative stress in early stage Bipolar Disorder and the association with response to lithium.

Authors:  Rafael T de Sousa; Carlos A Zarate; Marcus V Zanetti; Alana C Costa; Leda L Talib; Wagner F Gattaz; Rodrigo Machado-Vieira
Journal:  J Psychiatr Res       Date:  2013-12-06       Impact factor: 4.791

2.  Interaction of DRD2TaqI, COMT, and ALDH2 genes associated with bipolar II disorder comorbid with anxiety disorders in Han Chinese in Taiwan.

Authors:  Ming-Chuan Hu; Sheng-Yu Lee; Tzu-Yun Wang; Yun-Hsuan Chang; Shiou-Lan Chen; Shih-Heng Chen; Chun-Hsien Chu; Chen-Lin Wang; I Hui Lee; Po See Chen; Yen Kuang Yang; Ru-Band Lu
Journal:  Metab Brain Dis       Date:  2014-11-29       Impact factor: 3.584

3.  A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.

Authors:  P S Chen; H H Chang; C-C Huang; C C Lee; S-Y Lee; S-L Chen; S-Y Huang; Y K Yang; R-B Lu
Journal:  Pharmacogenomics J       Date:  2016-02-09       Impact factor: 3.550

Review 4.  Peripheral blood brain-derived neurotrophic factor in bipolar disorder: a comprehensive systematic review and meta-analysis.

Authors:  K Munkholm; M Vinberg; L V Kessing
Journal:  Mol Psychiatry       Date:  2015-07-21       Impact factor: 15.992

Review 5.  Association between brain-derived neurotrophic factor genetic polymorphism Val66Met and susceptibility to bipolar disorder: a meta-analysis.

Authors:  Zuowei Wang; Zezhi Li; Keming Gao; Yiru Fang
Journal:  BMC Psychiatry       Date:  2014-12-24       Impact factor: 3.630

6.  Relationship between personality disorder functioning styles and the emotional states in bipolar I and II disorders.

Authors:  Jiashu Yao; You Xu; Yanhua Qin; Jing Liu; Yuedi Shen; Wei Wang; Wei Chen
Journal:  PLoS One       Date:  2015-01-27       Impact factor: 3.240

7.  Fluvoxamine induced oculogyric dystonia and manic switch in a patient with obsessive compulsive disorder.

Authors:  Sai Krishna Tikka; Shobit Garg; Basudeb Das
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.